Encephalomyelitis: Clinical Trials

14 trials for Encephalomyelitis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

11 completed, 2 unknown, 1 recruiting. 14 Phase 3, 6 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 314Completed 11, Unknown 2, Recruiting 1
Phase 26Completed 4, Recruiting 1, Unknown 1

Follow Encephalomyelitis: new trials by email Literature Review of Encephalomyelitis trials Research Report on Encephalomyelitis

Trials (filtered) newest first · largest first

All 14 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
RCT of Efficacy and Safety of CP003 on CFS/ME or Post COVID-19 Fatigue
LingZhi capsule - Chronic Fatigue Syndrome (CFS), Post-COVID ME/CFS
Phase 2 / Phase 3RecruitingThe University of Hong Kong1302025-01-022026-09-21
Effect of Metformin in Reducing Fatigue in Long COVID in Adolescents
Metformin, Placebo - Long COVID
Phase 3UnknownPurpose Life Sciences162024-04-012024-03-04
A Multicenter, Adaptive, Randomized, doublE-blinded, Placebo-controlled Study in Participants With Long COVID-19: The REVIVE Trial
Fluvoxamine Maleate 100 MG, Placebo, Metformin Extended Release Oral Tablet - Long COVID-19 Syndrome, Chronic Fatigue Syndrome
Phase 3CompletedCardresearch3992023-10-182026-04-13
Prednisolone and Vitamin B1/6/12 in Patients With Post-Covid-Syndrome
Prednisolone 20 mg/ 5 mg, Vitamin B compound (100mg B1, 50 mg B6, 500 µg B12), Placebo for Vitamin B compound - Post-COVID-19 Syndrome
Phase 3CompletedWuerzburg University Hospital3212022-11-112025-04-01
Investigating the Role of Early Intravenous Immunoglobulin Treatment for Children With Encephalitis
Immunoglobulins, Intravenous (Privigen), Placebo - Encephalitis
Phase 3CompletedUniversity of Oxford182016-01-012024-03-04
B-lymphocyte Depletion Using Rituximab in Chronic Fatigue Syndrome/ Myalgic Encephalopathy (CFS/ME). A Randomized Phase-III Study.
Rituximab, Placebo - Chronic Fatigue Syndrome/ Myalgic Encephalitis (CFS/ME)
Phase 3CompletedHaukeland University Hospital1512014-09-012021-05-11
Cytokine Inhibition in Chronic Fatigue Syndrome Patients
Anakinra, Placebo - Chronic Fatigue Syndrome
Phase 2 / Phase 3CompletedRadboud University Medical Center502014-06-012016-05-25
Clinical Trial to Evaluate the Effectiveness of Acupuncture as a Treatment in Patients Diagnosed With CFS.
Acupuncture. - Chronic Fatigue Syndrome., Muscular Diseases.
Phase 2 / Phase 3UnknownHospital Vall d'Hebron602013-02-012013-08-29
Clinical Trial to Measure the Maximun HR After ReConnect ® Supplementation vs. Placebo in CFS.
ReConnect (NADH plus CoQ10), placebo - Chronic Fatigue Syndrome
Phase 2 / Phase 3CompletedHospital Universitari Vall d'Hebron Research Institute802013-01-012015-02-19
Investigator Initiated Clinical Study to Explore the Efficacy and Safety of Human Placenta Hydrolysate in the Chronic Fatigue Patients
GCJBP Laennec Inj., Placebo - Chronic Fatigue Syndrome, Idiopathic Chronic Fatigue
Phase 3CompletedHo Cheol Shin, M.D., Ph.D.782013-01-012013-09-26
Drug Intervention in Chronic Fatigue Syndrome
Rituximab, Saline (NaCl 0,9 %) (placebo) - Chronic Fatigue Syndrome
Phase 2 / Phase 3CompletedHaukeland University Hospital302008-06-012021-05-11
Pilot, Opened, Randomized Clinical Trial to Assess the Efficacy of Duloxetine in the Treatment of Fibromialgy in Patients With Infection by HIV 1+
Duloxetine 60 mg, QD - Fibromyalgia, HIV-1 Infection
Phase 3CompletedGermans Trias i Pujol Hospital102007-01-012019-12-04
Double Blind Trial of Duloxetine in Chronic Fatigue Syndrome
Duloxetine, Placebo - Fatigue Syndrome, Chronic
Phase 2 / Phase 3CompletedUniversity of Cincinnati602006-09-012015-08-21
The Study of the Safety and Efficacy of Ampligen in Chronic Fatigue Syndrome
Ampligen - Chronic Fatigue Syndrome, Myalgic Encephalomyelitis
Phase 3CompletedAIM ImmunoTech Inc.2341998-12-012013-04-17

Narrower conditions

Fatigue Syndrome, Chronic (13)  ·  Fatigue (4)  ·  Pain (3)  ·  Post-Acute COVID-19 Syndrome (3)  ·  Fibromyalgia (2)  ·  Central Nervous System Diseases (1)  ·  Central Nervous System Infections (1)  ·  Cognitive Dysfunction (1)  ·  Encephalitis (1)  ·  Meningoencephalitis (1)  ·  Muscular Diseases (1)  ·  Parasomnias (1)

Broader conditions

Nervous System Diseases (14)  ·  Neuroinflammatory Diseases (14)  ·  Chronic Disease (13)  ·  Disease Attributes (13)  ·  Musculoskeletal Diseases (13)  ·  Neuromuscular Diseases (13)  ·  Pathologic Processes (13)  ·  Pathological Conditions, Signs and Symptoms (13)  ·  Muscular Diseases (12)  ·  Signs and Symptoms (6)  ·  Infections (4)  ·  COVID-19 (3)  ·  Coronaviridae Infections (3)  ·  Coronavirus Infections (3)

Interventions

Sodium Chloride (3)  ·  Duloxetine Hydrochloride (2)  ·  Rituximab (2)  ·  Acupuncture Therapy (1)  ·  Ascorbic Acid (1)  ·  Fluvoxamine (1)  ·  Immunoglobulins (1)  ·  Immunoglobulins, Intravenous (1)  ·  Interleukin 1 Receptor Antagonist Protein (1)  ·  Metformin (1)  ·  NAD (1)  ·  Phosphoserine (1)  ·  Prednisolone (1)  ·  Serine (1)  ·  Sugars (1)

Sponsors

Haukeland University Hospital (2)  ·  AIM ImmunoTech Inc. (1)  ·  Cardresearch (1)  ·  Germans Trias i Pujol Hospital (1)  ·  Ho Cheol Shin, M.D., Ph.D. (1)  ·  Hospital Universitari Vall d'Hebron Research Institute (1)  ·  Hospital Vall d'Hebron (1)  ·  Purpose Life Sciences (1)  ·  Radboud University Medical Center (1)  ·  The University of Hong Kong (1)  ·  University of Cincinnati (1)  ·  University of Oxford (1)  ·  Wuerzburg University Hospital (1)

Countries

Spain (3)  ·  Norway (2)  ·  Brazil (1)  ·  Germany (1)  ·  Hong Kong (1)  ·  Netherlands (1)  ·  Pakistan (1)  ·  South Korea (1)  ·  United Kingdom (1)  ·  United States (1)

Top investigators

Olav Mella, MD, PhD (2)  ·  Andrew J Pollard, FRCPCH, PhD (1)  ·  David R Strayer, MD (1)  ·  Gilmar Reis, MD,PhD. (1)  ·  Ho Cheol Shin, M.D., Ph.d. (1)  ·  Jimenez Gutierrez, Nurse (1)  ·  Jos van der Meer, Prof, PhD, MD (1)  ·  Jose Alegre-Martin, MD, PhD (1)  ·  Lesley M Arnold, MD (1)  ·  Negredo Eugenia, MD,PhD (1)  ·  Zamir Hussain Suhag, MBBS, FCPS (1)

Results publications

PMID 22039471, PMID 22431963, PMID 25386668, PMID 25660434, PMID 26212172, PMID 26438161, PMID 28265678, PMID 29284500, PMID 30934066, PMID 33119613, PMID 37945292, PMID 41558017, PMID 41911553, PMID 42832803

NIH funding

2014 (1)